Patient-reported improvements from use of IMC-2 alone and IMC-2 and Paxlovid® in a Long COVID cohort: a case series
This small, open-label case series provides pilot evidence supporting the need for a larger trial of combination antivirals for people living with LC. Based on these results, a larger, controlled trial of IMC-2 paired with Paxlovid is recommended.
Authors
- David Putrino (ORCID: https://orcid.org/0000-0002-2232-3324)
- William L. Pridgen
Institutions
- P.E. LaMoreaux & Associates (United States) (US)
- Tuscaloosa VA Medical Center (US)
- Tuscaloosa City Schools (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-05
- DOI
- https://doi.org/10.3389/fimmu.2025.1698271
- Primary Topic
- Long-Term Effects of COVID-19
- Type
- article
- Field-Weighted Citation Impact
- 0.00